Anyhow several oncology services also routinely test for BRAF V600E mutations in view of the recent approval of BRAF/MEK inhibitors for metastatic BRAF V600E–mutated NSCLC patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.